Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study (original) (raw)

References

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807–1812.
   Article CAS PubMed PubMed Central Google Scholar
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597–602.
   Article CAS PubMed Google Scholar
3. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7–11.
   Article CAS PubMed Google Scholar
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773.
   Article CAS PubMed PubMed Central Google Scholar
5. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 2009; 118: 469–474.
   Article PubMed Google Scholar
6. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009; 125: 353–355.
   Article CAS PubMed Google Scholar
7. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.
   Article CAS PubMed PubMed Central Google Scholar
8. Anderson JE, Kopecky KJ, Willman CL, Head D, O’Donnell MR, Luthardt FW et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100: 3869–3876.
   Article CAS PubMed Google Scholar
9. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113: 6558–6566.
   Article CAS PubMed PubMed Central Google Scholar
10. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329.
    CAS PubMed Google Scholar
11. Petersdorf SH, Rankin C, Head DR, Terebelo HR, Willman CL, Balcerzak SP et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hemato 2007; 82: 1056–1062.
    Article CAS Google Scholar
12. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589–3595.
    Article CAS PubMed Google Scholar
13. Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006; 107: 3724–3726.
    Article CAS PubMed PubMed Central Google Scholar
14. Hayden JT, Fruhwald MC, Hasselblatt M, Ellison DW, Bailey S, Clifford SC . Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 2009; 8: 1806–1807.
    Article CAS PubMed Google Scholar
15. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261–265.
    Article CAS PubMed PubMed Central Google Scholar
16. Walmsley SR, Chilvers ER, Whyte MK . Hypoxia, hypoxia inducible factor and myeloid cell function. Arthritis Res Ther 2009; 11: 219–226.
    Article PubMed PubMed Central Google Scholar
17. Jiang BH, Liu LZ . PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19–65.
    Article CAS PubMed PubMed Central Google Scholar
18. Onnis B, Rapisarda A, Melillo G . Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009; 13: 2780–2786 .
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank the patients and families who consented to the use of biologic specimens in these trials. We also thank the AML Reference Laboratories of the COG and SWOG for providing diagnostic specimens, and Dr Cherise Guess for scientific editing. This work was supported by the National Institutes of Health (Grants No. K23 CA92405, CA18029, CA32102, CA114563, R01 CA114563-01, R21 CA102624, R21 CA10262-01, U10 CA032102-30, CA38926, CA20319, CA27057, CA12213 and Children's Oncology Group Chair's Grant NIH U10 CA98543).Authorship: PH designed research, performed research, analyzed data and wrote the article. TAA and KJK served as senior statisticians, performed statistical analyses and edited the article. KLM, JK and RZ performed research and edited the article. RBG performed statistical analyses and edited the article. SCR, BAH, VO, CAH, JLF, ASG, SHP, JEA, GHR, LB, CLW, IDB, JPR, FRA and DLS analyzed data and edited the article. SM designed research, analyzed data and wrote the article.

Author information

Authors and Affiliations

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
   P A Ho, K L Miller, J Kuhn, R Zeng, V Oehler, I D Bernstein, J P Radich, F R Appelbaum, D L Stirewalt & S Meshinchi
2. Division of Pediatric Hematology/Oncology, University of Washington School of Medicine, Seattle, WA, USA
   P A Ho, I D Bernstein & S Meshinchi
3. Department of Biostatistics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
   T A Alonzo
4. Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
   K J Kopecky
5. Biostatistics, Children's Oncology Group, Arcadia, CA, USA
   R B Gerbing
6. Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
   S C Raimondi
7. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
   B A Hirsch
8. Division of Medical Oncology, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA, USA
   V Oehler, S H Petersdorf, J P Radich, F R Appelbaum & D L Stirewalt
9. Clinical Development, Reata Pharma, Dallas, TX, USA
   C A Hurwitz
10. Department of Pediatrics, University of Southern California, Los Angeles, CA, USA
    J L Franklin
11. Amgen Incorporated, Thousand Oaks, CA, USA
    J L Franklin
12. Division of Hematology/Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA
    A S Gamis
13. Katmai Oncology Group, Anchorage, AK, USA
    J E Anderson
14. School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA
    G H Reaman
15. School of Medicine, University of Michigan, Ann Arbor, MI, USA
    L H Baker
16. UNM Cancer Research Facility, University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM, USA
    C L Willman

Authors

1. P A Ho
   You can also search for this author inPubMed Google Scholar
2. T A Alonzo
   You can also search for this author inPubMed Google Scholar
3. K J Kopecky
   You can also search for this author inPubMed Google Scholar
4. K L Miller
   You can also search for this author inPubMed Google Scholar
5. J Kuhn
   You can also search for this author inPubMed Google Scholar
6. R Zeng
   You can also search for this author inPubMed Google Scholar
7. R B Gerbing
   You can also search for this author inPubMed Google Scholar
8. S C Raimondi
   You can also search for this author inPubMed Google Scholar
9. B A Hirsch
   You can also search for this author inPubMed Google Scholar
10. V Oehler
    You can also search for this author inPubMed Google Scholar
11. C A Hurwitz
    You can also search for this author inPubMed Google Scholar
12. J L Franklin
    You can also search for this author inPubMed Google Scholar
13. A S Gamis
    You can also search for this author inPubMed Google Scholar
14. S H Petersdorf
    You can also search for this author inPubMed Google Scholar
15. J E Anderson
    You can also search for this author inPubMed Google Scholar
16. G H Reaman
    You can also search for this author inPubMed Google Scholar
17. L H Baker
    You can also search for this author inPubMed Google Scholar
18. C L Willman
    You can also search for this author inPubMed Google Scholar
19. I D Bernstein
    You can also search for this author inPubMed Google Scholar
20. J P Radich
    You can also search for this author inPubMed Google Scholar
21. F R Appelbaum
    You can also search for this author inPubMed Google Scholar
22. D L Stirewalt
    You can also search for this author inPubMed Google Scholar
23. S Meshinchi
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toS Meshinchi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

About this article

Cite this article

Ho, P., Alonzo, T., Kopecky, K. et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.Leukemia 24, 909–913 (2010). https://doi.org/10.1038/leu.2010.56

Download citation

• Received: 20 January 2010
• Revised: 23 February 2010
• Accepted: 03 March 2010
• Published: 08 April 2010
• Issue Date: May 2010
• DOI: https://doi.org/10.1038/leu.2010.56

Keywords